Skip to main content

Table 2 Demographic and clinical characteristics of hypohidrosis or anhidrosis cases collected from the FAERS database

From: Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis

Characteristics

Total reports, N. (%)

Reports by the healthcare professionals, N. (%)

540

213

Gender

 F

263 (48.70)

96 (45.07)

 M

229 (42.41)

90 (42.25)

 Unknown

48 (8.89)

27 (12.68)

Age group (years)

  < 18

74 (13.70)

41 (19.25)

 18–44

128 (23.70)

60 (28.17)

 45–64

131 (24.26)

43 (20.19)

 65–74

22 (4.07)

8 (3.76)

 75–84

10 (1.85)

2 (0.94)

  > 85

3 (0.56)

2 (0.94)

 Unknown

172 (31.85)

57 (26.76)

Reporting Area

 Asia

67 (12.41)

46 (21.60)

 Europe

91 (16.85)

51 (23.94)

 North America

352 (65.19)

102 (47.89)

 Oceania

2 (0.37)

–

 South America

4 (0.74)

2 (0.94)

 Unknown

24 (4.44)

12 (5.63)

Reporters

 Consumer

249 (46.11)

–

 Lawyer

6 (1.11)

–

 Other health professionals

99 (18.33)

99 (46.48)

 Physician

98 (18.15)

98 (46.01)

 Pharmacist

16 (2.96)

16 (7.51)

 Unknown

72 (13.33)

–

Reporting Year

 2004

18 (3.33)

10 (4.69)

 2005

11 (2.04)

5 (2.35)

 2006

20 (3.70)

4 (1.88)

 2007

9 (1.67)

3 (1.41)

 2008

13 (2.41)

6 (2.82)

 2009

17 (3.15)

6 (2.82)

 2010

29 (5.37)

14 (6.57)

 2011

14 (2.59)

3 (1.41)

 2012

16 (2.96)

5 (2.35)

 2013

30 (5.56)

12 (5.63)

 2014

55 (10.19)

19 (8.92)

 2015

30 (5.56)

13 (6.10)

 2016

50 (9.26)

25 (11.74)

 2017

36 (6.67)

17 (7.98)

 2018

66 (12.22)

43 (20.19)

 2019

36 (6.67)

11 (5.16)

 2020

48 (8.89)

9 (4.23)

 2021

39 (7.22)

7 (3.29)

 Unknown

3 (0.56)

1 (0.47)

Outcome

 Congenital anomaly

2 (0.52)

–

 Death

9 (2.33)

7 (4.00)

 Disability

51 (13.21)

11 (6.29)

 Hospitalization

146 (37.82)

75 (42.86)

 Life-threatening

55 (14.25)

35 (20.00)

 Other serious (important medical events)

297 (76.94)

134 (76.57)

 Required intervention to prevent permanent impairment/damage

10 (2.59)

4 (2.29)